drugset / Trial / NCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NaSequentialOpen-labelTreatment
Summary
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2029-07
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPI-326 | Unknown | — | Intravenous |